Georg Widhalm

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/485137/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology, 2015, 17, 1064-1075.	1.2	485
2	Longitudinal molecular trajectories of diffuse glioma in adults. Nature, 2019, 576, 112-120.	27.8	320
3	What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas?. Neurosurgery, 2015, 77, 663-673.	1.1	272
4	Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncolmmunology, 2016, 5, e1057388.	4.6	239
5	The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nature Medicine, 2018, 24, 1611-1624.	30.7	229
6	Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro-Oncology, 2017, 19, 1460-1468.	1.2	213
7	5â€Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement. Cancer, 2010, 116, 1545-1552.	4.1	199
8	Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. ESMO Open, 2016, 1, e000024.	4.5	152
9	5-Aminolevulinic Acid Induced Fluorescence Is a Powerful Intraoperative Marker for Precise Histopathological Grading of Gliomas with Non-Significant Contrast-Enhancement. PLoS ONE, 2013, 8, e76988.	2.5	138
10	Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). Journal of Neuro-Oncology, 2016, 130, 19-29.	2.9	107
11	PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). , 2014, 33, 42-49.		100
12	Atypical teratoid rhabdoid tumor: improved longâ€ŧerm survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992–2012. Cancer Medicine, 2014, 3, 91-100.	2.8	99
13	Tumourâ€infiltrating lymphocytes and expression of programmed death ligand 1 (PDâ€L1) in melanoma brain metastases. Histopathology, 2015, 66, 289-299.	2.9	99
14	Strong 5-aminolevulinic acid-induced fluorescence is a novel intraoperative marker for representative tissue samples in stereotactic brain tumor biopsies. Neurosurgical Review, 2012, 35, 381-391.	2.4	86
15	Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases. European Radiology, 2017, 27, 3167-3173.	4.5	80
16	Analysis of the surgical benefits of 5-ALA–induced fluorescence in intracranial meningiomas: experience in 204 meningiomas. Journal of Neurosurgery, 2016, 125, 1408-1419.	1.6	69
17	Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. ESMO Open, 2018, 3, e000262.	4.5	69
18	Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial. Cancers, 2018, 10, 372.	3.7	67

#	Article	IF	CITATIONS
19	Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases. Clinical and Experimental Metastasis, 2013, 30, 357-368.	3.3	66
20	High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. Lung Cancer, 2014, 83, 83-89.	2.0	63
21	High correlation of temporal muscle thickness with lumbar skeletal muscle cross-sectional area in patients with brain metastases. PLoS ONE, 2018, 13, e0207849.	2.5	63
22	Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases. Journal of Neuro-Oncology, 2018, 140, 173-178.	2.9	62
23	Long-term outcome of a multidisciplinary concept of spinal dural arteriovenous fistulae treatment. Neuroradiology, 2008, 50, 67-74.	2.2	60
24	Plasma MicroRNA-21 Concentration May Be a Useful Biomarker in Glioblastoma Patients. Cancer Investigation, 2012, 30, 615-621.	1.3	60
25	ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer, 2013, 80, 278-283.	2.0	59
26	Sarcopenia in Neurological Patients: Standard Values for Temporal Muscle Thickness and Muscle Strength Evaluation. Journal of Clinical Medicine, 2020, 9, 1272.	2.4	56
27	Analysis of 5-aminolevulinic acid–induced fluorescence in 55 different spinal tumors. Neurosurgical Focus, 2014, 36, E11.	2.3	55
28	A novel miniature robotic guidance device for stereotactic neurosurgical interventions: preliminary experience with the iSYS1 robot. Journal of Neurosurgery, 2017, 126, 985-996.	1.6	55
29	αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer. Clinical and Experimental Metastasis, 2014, 31, 841-851.	3.3	51
30	Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases. Neuropathology and Applied Neurobiology, 2015, 41, e41-55.	3.2	49
31	Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches. , 2012, 31, 352-360.		49
32	O ⁶ â€methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas. Cancer, 2009, 115, 1070-1080.	4.1	48
33	Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurgical Review, 2013, 36, 45-56.	2.4	48
34	The value of visible 5-ALA fluorescence and quantitative protoporphyrin IX analysis for improved surgery of suspected low-grade gliomas. Journal of Neurosurgery, 2020, 133, 79-88.	1.6	48
35	5-ALA–induced fluorescence as a marker for diagnostic tissue in stereotactic biopsies of intracranial lymphomas: experience in 41 patients. Neurosurgical Focus, 2018, 44, E7.	2.3	46
36	Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma. , 2014, 33, 6-14.		45

#	Article	IF	CITATIONS
37	Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors. Journal of Neuro-Oncology, 2012, 109, 331-339.	2.9	43
38	Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases. Strahlentherapie Und Onkologie, 2014, 190, 676-685.	2.0	42
39	The Role of 5-ALA in Low-Grade Gliomas and the Influence of Antiepileptic Drugs on Intraoperative Fluorescence. Frontiers in Oncology, 2019, 9, 423.	2.8	42
40	Introduction of a standardized multimodality image protocol for navigation-guided surgery of suspected low-grade gliomas. Neurosurgical Focus, 2015, 38, E4.	2.3	39
41	Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma. Tumor Biology, 2016, 37, 1173-1182.	1.8	39
42	Value of 1H-magnetic resonance spectroscopy chemical shift imaging for detection of anaplastic foci in diffusely infiltrating gliomas with non-significant contrast-enhancement. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 512-520.	1.9	38
43	Preoperative Diffusion-Weighted Imaging of Single Brain Metastases Correlates with Patient Survival Times. PLoS ONE, 2013, 8, e55464.	2.5	38
44	High-resolution metabolic imaging of high-grade gliomas using 7T-CRT-FID-MRSI. NeuroImage: Clinical, 2020, 28, 102433.	2.7	37
45	Myeloid sarcoma with multiple lesions of the central nervous system in a patient without leukemia. Journal of Neurosurgery, 2006, 105, 916-919.	1.6	36
46	The value of intraoperative motor evoked potential monitoring during surgical intervention for thoracic idiopathic spinal cord herniation. Journal of Neurosurgery: Spine, 2012, 16, 114-126.	1.7	35
47	Systematic histopathological analysis of different 5-aminolevulinic acid–induced fluorescence levels in newly diagnosed glioblastomas. Journal of Neurosurgery, 2018, 129, 341-353.	1.6	35
48	Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. Journal of Neurosurgery, 2009, 111, 563-571.	1.6	34
49	Relative survival of patients with non-malignant central nervous system tumours: a descriptive study by the Austrian Brain Tumour Registry. British Journal of Cancer, 2014, 110, 286-296.	6.4	33
50	High-resolution metabolic mapping of gliomas via patch-based super-resolution magnetic resonance spectroscopic imaging at 7T. Neurolmage, 2019, 191, 587-595.	4.2	33
51	Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). Neuro-Oncology, 2013, 15, 112-121.	1.2	31
52	Brain tumours at 7T MRI compared to 3T—contrast effect after half and full standard contrast agent dose: initial results. European Radiology, 2015, 25, 106-112.	4.5	31
53	5-aminolevulinic acid induced protoporphyrin IX (ALA-PpIX) fluorescence guidance in meningioma surgery. Journal of Neuro-Oncology, 2019, 141, 555-565.	2.9	31
54	Intraoperative visualization of brain tumors with 5-aminolevulinic acid-induced fluorescence. , 2014, 33, 260-278.		31

#	Article	IF	CITATIONS
55	Brain Tumor Surgery With 3-Dimensional Surface Navigation. Operative Neurosurgery, 2012, 71, ons286-ons295.	0.8	30
56	The veins of the nucleus dentatus: Anatomical and radiological findings. NeuroImage, 2011, 54, 74-79.	4.2	29
57	Is Intraoperative Pathology Needed if 5-Aminolevulinic-Acid-Induced Tissue Fluorescence Is Found in Stereotactic Brain Tumor Biopsy?. Neurosurgery, 2020, 86, 366-373.	1.1	29
58	Computer-assisted and fractal-based morphometric assessment of microvascularity in histological specimens of gliomas. Scientific Reports, 2012, 2, 429.	3.3	28
59	Widefield fluorescence lifetime imaging of protoporphyrin IX for fluorescenceâ€guided neurosurgery: An ex vivo feasibility study. Journal of Biophotonics, 2019, 12, e201800378.	2.3	28
60	Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non–small cell lung cancer brain metastases. Cancer, 2020, 126, 4341-4352.	4.1	27
61	Prognostic impact of genetic alterations and methylation classes in meningioma. Brain Pathology, 2022, 32, e12970.	4.1	27
62	Correlation of microvascular fractal dimension with positron emission tomography [11C]-methionine uptake in glioblastoma multiforme: Preliminary findings. Microvascular Research, 2010, 80, 267-273.	2.5	26
63	Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors. British Journal of Cancer, 2012, 107, 1454-1458.	6.4	26
64	Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status. European Radiology, 2017, 27, 1556-1567.	4.5	26
65	Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases—development and validation of the LabBM score. Neuro-Oncology, 2017, 19, now290.	1.2	26
66	The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma. Radiotherapy and Oncology, 2017, 125, 228-233.	0.6	26
67	5-ALA in Suspected Low-Grade Gliomas: Current Role, Limitations, and New Approaches. Frontiers in Oncology, 2021, 11, 699301.	2.8	26
68	Amplification and overexpression of <i><scp>CMET</scp></i> is a common event in brain metastases of nonâ€small cell lung cancer. Histopathology, 2014, 65, 684-692.	2.9	25
69	Alleviation of Brain Edema and Restoration of Functional Independence by Bevacizumab in Brain-Metastatic Breast Cancer: A Case Report. Breast Care, 2014, 9, 134-134.	1.4	25
70	Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: A retrospective analysis of 624 patients. European Journal of Cancer Care, 2017, 26, e12707.	1.5	25
71	The prognostic value of [123I]-vascular endothelial growth factor ([123I]-VEGF) in glioma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2396-2403.	6.4	25
72	Beyond backscattering: optical neuroimaging by BRAD. Biomedical Optics Express, 2018, 9, 2476.	2.9	25

#	Article	IF	CITATIONS
73	Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma. Journal of Neuro-Oncology, 2020, 148, 187-198.	2.9	25
74	A management algorithm for cerebrospinal fluid leak associated with anterior skull base fractures: detailed clinical and radiological follow-up. Neurosurgical Review, 2012, 35, 227-238.	2.4	24
75	Macroscopic fluorescence-lifetime imaging of NADH and protoporphyrin IX improves the detection and grading of 5-aminolevulinic acid-stained brain tumors. Scientific Reports, 2020, 10, 20492.	3.3	24
76	Arterial Spin-Labeling Assessment of Normalized Vascular Intratumoral Signal Intensity as a Predictor of Histologic Grade of Astrocytic Neoplasms. American Journal of Neuroradiology, 2014, 35, 482-489.	2.4	23
77	Visual and semiquantitative 11C-methionine PET: an independent prognostic factor for survival of newly diagnosed and treatment-naÃ ⁻ ve gliomas. Neuro-Oncology, 2018, 20, 411-419.	1.2	22
78	LAC-3 expression in the inflammatory microenvironment of glioma. Journal of Neuro-Oncology, 2021, 152, 533-539.	2.9	22
79	Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center. Clinical and Experimental Metastasis, 2018, 35, 727-738.	3.3	21
80	Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases. British Journal of Cancer, 2021, 124, 1294-1300.	6.4	21
81	Evaluation of the Temporal Muscle Thickness as an Independent Prognostic Biomarker in Patients with Primary Central Nervous System Lymphoma. Cancers, 2021, 13, 566.	3.7	21
82	A novel robot-guided minimally invasive technique for brain tumor biopsies. Journal of Neurosurgery, 2020, 132, 150-158.	1.6	21
83	Distributed changes of the functional connectome in patients with glioblastoma. Scientific Reports, 2020, 10, 18312.	3.3	19
84	Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors. Npj Vaccines, 2020, 5, 5.	6.0	19
85	5-ALA Fluorescence Is a Powerful Prognostic Marker during Surgery of Low-Grade Gliomas (WHO) Tj ETQq1 1 0.7	784314 rg 3.7	BT /Overlock
86	Improved susceptibility weighted imaging at ultra-high field using bipolar multi-echo acquisition and optimized image processing: CLEAR-SWI. NeuroImage, 2021, 237, 118175.	4.2	19
87	Detailed analysis of 5-aminolevulinic acid induced fluorescence in different brain metastases at two specialized neurosurgical centers: experience in 157 cases. Journal of Neurosurgery, 2020, 133, 1032-1043.	1.6	19
88	Strength of skeletal muscle and self-reported physical performance in Austrian glioblastoma-patients. Wiener Klinische Wochenschrift, 2012, 124, 377-383.	1.9	18
89	Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years. European Journal of Cancer, 2022, 162, 170-181.	2.8	18
90	Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours. ESMO Open, 2020, 5, e000863.	4.5	17

#	Article	IF	CITATIONS
91	Robust Deep Learning–based Segmentation of Glioblastoma on Routine Clinical MRI Scans Using Sparsified Training. Radiology: Artificial Intelligence, 2020, 2, e190103.	5.8	16
92	Revealing brain pathologies with multimodal visible light optical coherence microscopy and fluorescence imaging. Journal of Biomedical Optics, 2019, 24, 1.	2.6	16
93	Frequent overexpression of ErbB – receptor family members in brain metastases of nonâ€small cell lung cancer patients. Apmis, 2013, 121, 1144-1152.	2.0	15
94	Vascular endothelia growth factor targeted therapy may improve the effect of dendritic cell-based cancer immune therapy. International Journal of Clinical Pharmacology and Therapeutics, 2014, 52, 76-77.	0.6	15
95	Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens. Journal of Neuro-Oncology, 2013, 112, 347-354.	2.9	14
96	Perioperative imaging in patients treated with resection of brain metastases: a survey by the European Association of Neuro-Oncology (EANO) Youngsters committee. BMC Cancer, 2020, 20, 410.	2.6	14
97	Quantifying eloquent locations for glioblastoma surgery using resection probability maps. Journal of Neurosurgery, 2021, 134, 1091-1101.	1.6	14
98	Influence of preoperative corticosteroid treatment on rate of diagnostic surgeries in primary central nervous system lymphoma: a multicenter retrospective study. BMC Cancer, 2021, 21, 754.	2.6	14
99	Prognostic assessment in patients with newly diagnosed small cell lung cancer brain metastases: results from a real-life cohort. Journal of Neuro-Oncology, 2019, 145, 85-95.	2.9	13
100	Ex-vivo analysis of quantitative 5-ALA fluorescence intensity in diffusely infiltrating gliomas using a handheld spectroscopic probe: Correlation with histopathology, proliferation and microvascular density. Photodiagnosis and Photodynamic Therapy, 2019, 27, 354-361.	2.6	13
101	Improved Diagnostic Imaging of Brain Tumors by Multimodal Microscopy and Deep Learning. Cancers, 2020, 12, 1806.	3.7	13
102	Prognostic Value of 5-ALA Fluorescence, Tumor Cell Infiltration and Angiogenesis in the Peritumoral Brain Tissue of Brain Metastases. Cancers, 2021, 13, 603.	3.7	12
103	Fluorescence Lifetime Imaging and Spectroscopic Co-Validation for Protoporphyrin IX-Guided Tumor Visualization in Neurosurgery. Frontiers in Oncology, 2021, 11, 741303.	2.8	12
104	Are hypothyroidism and hypogonadism clinically relevant in patients with malignant gliomas? A longitudinal trial in patients with glioma. Radiotherapy and Oncology, 2019, 130, 139-148.	0.6	11
105	PSMA Expression in 122 Treatment Naive Glioma Patients Related to Tumor Metabolism in 11C-Methionine PET and Survival. Journal of Personalized Medicine, 2021, 11, 624.	2.5	11
106	Towards real-time wide-field fluorescence lifetime imaging of 5-ALA labeled brain tumors with multi-tap CMOS cameras. Biomedical Optics Express, 2020, 11, 1598.	2.9	11
107	QSMxT: Robust masking and artifact reduction for quantitative susceptibility mapping. Magnetic Resonance in Medicine, 2022, 87, 1289-1300.	3.0	11
108	A Novel Protocol of Continuous Navigation Guidance for Endoscopic Third Ventriculostomy. Operative Neurosurgery, 2014, 10, 514-524.	0.8	10

#	Article	IF	CITATIONS
109	Sorafenib for patients with pretreated recurrent or progressive high-grade glioma. Anti-Cancer Drugs, 2014, 25, 723-728.	1.4	10
110	Haematopoietic stem cell transplantation for treatment of primary <scp>CNS</scp> lymphoma: singleâ€centre experience and literature review. European Journal of Haematology, 2015, 95, 75-82.	2.2	10
111	Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer. European Journal of Cancer, 2020, 135, 150-158.	2.8	10
112	Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma. Cancer Immunology, Immunotherapy, 2021, 70, 3643-3650.	4.2	10
113	Prognostic factors in adult brainstem glioma: a tertiary care center analysis and review of the literature. Journal of Neurology, 2022, 269, 1574-1590.	3.6	10
114	Glutamine anaplerosis is required for amino acid biosynthesis in human meningiomas. Neuro-Oncology, 2022, 24, 556-568.	1.2	10
115	Surgical microscope with integrated fluorescence lifetime imaging for 5-aminolevulinic acid fluorescence-guided neurosurgery. Journal of Biomedical Optics, 2020, 25, 1.	2.6	10
116	High Interobserver Agreement in the Subjective Classification of 5â€Aminolevulinic Acid Fluorescence Levels in Newly Diagnosed Glioblastomas. Lasers in Surgery and Medicine, 2020, 52, 814-821.	2.1	9
117	Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110090.	3.2	9
118	Glioblastoma Surgery Imaging–Reporting and Data System: Validation and Performance of the Automated Segmentation Task. Cancers, 2021, 13, 4674.	3.7	9
119	MR Fingerprinting—A Radiogenomic Marker for Diffuse Gliomas. Cancers, 2022, 14, 723.	3.7	9
120	Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study. Acta Oncológica, 2019, 58, 967-976.	1.8	8
121	TCGA mRNA Expression Analysis of the Heme Biosynthesis Pathway in Diffusely Infiltrating Gliomas: A Comparison of Typically 5-ALA Fluorescent and Non-Fluorescent Gliomas. Cancers, 2020, 12, 2043.	3.7	8
122	Postoperative Magnetic Resonance Imaging After Surgery of Brain Metastases: Analysis of Extent of Resection and Potential Risk Factors for Incomplete Resection. World Neurosurgery, 2020, 143, e365-e373.	1.3	7
123	In Reply: Is Intraoperative Pathology Needed if 5-Aminolevulinic-Acid-Induced Tissue Fluorescence Is Found in Stereotactic Brain Tumor Biopsy?. Neurosurgery, 2020, 87, E427-E427.	1.1	7
124	High Diagnostic Accuracy of Visible 5â€ALA Fluorescence in Meningioma Surgery According to Histopathological Analysis of Tumor Bulk and Peritumoral Tissue. Lasers in Surgery and Medicine, 2021, 53, 300-308.	2.1	7
125	Outcome evaluation in glioblastoma patients older than 65 years: Importance of individual assessment of treatment tolerance. , 2014, 33, 399-406.		7
126	Heme Biosynthesis Factors and 5-ALA Induced Fluorescence: Analysis of mRNA and Protein Expression in Fluorescing and Non-fluorescing Gliomas. Frontiers in Medicine, 2022, 9, .	2.6	7

#	Article	IF	CITATIONS
127	MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy. Cancers, 2022, 14, 1579.	3.7	6
128	Efficacy, Outcome, and Safety of Elderly Patients with Glioblastoma in the 5-ALA Era: Single Center Experience of More Than 10 Years. Cancers, 2021, 13, 6119.	3.7	6
129	Noninvasive Differentiation of Meningiomas and Dural Metastases Using Intratumoral Vascularity Obtained by Arterial Spin Labeling. Clinical Neuroradiology, 2020, 30, 599-605.	1.9	5
130	Influence of Corticosteroids and Antiepileptic Drugs on Visible 5-Aminolevulinic Acid Fluorescence in a Series of Initially Suspected Low-Grade Gliomas Including World Health Organization Grade II, III, and IV Gliomas. World Neurosurgery, 2020, 137, e437-e446.	1.3	5
131	Heme Biosynthesis mRNA Expression Signature: Towards a Novel Prognostic Biomarker in Patients with Diffusely Infiltrating Gliomas. Cancers, 2021, 13, 662.	3.7	5
132	5-ALA fluorescence for intraoperative visualization of spinal ependymal tumors and identification of unexpected residual tumor tissue: experience in 31 patients. Journal of Neurosurgery: Spine, 2021, 34, 374-382.	1.7	5
133	Glioblastoma Surgery Imaging—Reporting and Data System: Standardized Reporting of Tumor Volume, Location, and Resectability Based on Automated Segmentations. Cancers, 2021, 13, 2854.	3.7	5
134	The prognostic value of cognition in patients with glioblastoma multiforme Journal of Clinical Oncology, 2013, 31, 2078-2078.	1.6	5
135	Enhanced expression of autophagyâ€related p62 without increased deposits of neurodegenerationâ€associated proteins in glioblastoma and surrounding tissue – An autopsyâ€based study. Brain Pathology, 2022, 32, e13058.	4.1	5
136	Bioimaging and surgery of brain tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 535-545.	1.8	4
137	Timing of glioblastoma surgery and patient outcomes: a multicenter cohort study. Neuro-Oncology Advances, 2021, 3, vdab053.	0.7	4
138	PD1 and PD-L1 expression in glioblastoma Journal of Clinical Oncology, 2014, 32, 2011-2011.	1.6	4
139	Lymphocyte-activation gene 3 (LAC-3) expression in the inflammatory microenvironment of glioma Journal of Clinical Oncology, 2020, 38, 2553-2553.	1.6	4
140	Cardiac transplantation and simultaneous surgical repair of an aortic aneurysm. Annals of Thoracic Surgery, 1999, 68, 1391-1392.	1.3	3
141	Plasma PD-L1 concentration in patients with brain metastases from solid tumors Journal of Clinical Oncology, 2015, 33, e13026-e13026.	1.6	3
142	Clinical neuropathology practice guide 1-2013: Molecular subtyping of glioblastoma: ready for clinical use?. , 2013, 32, 5-8.		3
143	Influence of dexamethasone on visible 5-ALA fluorescence and quantitative protoporphyrin IX accumulation measured by fluorescence lifetime imaging in glioblastomas: is pretreatment obligatory before fluorescence-guided surgery?. Journal of Neurosurgery, 2022, 136, 1542-1550.	1.6	3
144	Does pigmentation, hemosiderin and blood effect visible 5-ALA fluorescence in cerebral melanoma metastasis?. Photodiagnosis and Photodynamic Therapy, 2022, 39, 102864.	2.6	3

#	Article	IF	CITATIONS
145	7T HR FID-MRSI Compared to Amino Acid PET: Glutamine and Glycine as Promising Biomarkers in Brain Tumors. Cancers, 2022, 14, 2163.	3.7	3
146	Prediction of glioma-subtypes: comparison of performance on a DL classifier using bounding box areas versus annotated tumors. BMC Biomedical Engineering, 2022, 4, 4.	2.6	3
147	The Association of Early Cognition Assessments and Progression-free Survival in Patients with Glioblastoma Multiforme. The Journal of Oncopathology, 2014, 1, 1-9.	0.1	2
148	On the cutting edge of glioblastoma surgery: where neurosurgeons agree and disagree on surgical decisions. Journal of Neurosurgery, 2022, 136, 45-55.	1.6	2
149	Androgen Receptor is Expressed in Breast Cancer Brain Metastases. Applied Immunohistochemistry and Molecular Morphology, 2021, Publish Ahead of Print, 728-733.	1.2	1
150	Association of tumor-infiltrating lymphocytes with brain edema and overall survival in brain metastases Journal of Clinical Oncology, 2014, 32, 2012-2012.	1.6	1
151	A randomized clinical trial for the treatment of glioblastoma multiforme with the individualized dendritic cell-based cancer immunotherapy AV0113 Journal of Clinical Oncology, 2014, 32, 2052-2052.	1.6	1
152	Correlation of plasma PD-L1 detectability with age in glioma patients Journal of Clinical Oncology, 2015, 33, e13039-e13039.	1.6	1
153	Descriptive analysis of 2419 patients with brain metastases of solid cancers: A real life cohort Journal of Clinical Oncology, 2016, 34, 2072-2072.	1.6	1
154	PD-L1 expression and tumor infiltrating lymphocytes (TIL) in brain metastases (BM) of small cell lung cancer (SCLC) Journal of Clinical Oncology, 2016, 34, 8563-8563.	1.6	1
155	Primary tumor sidedness associates with prognosis of patients with brain metastases of colorectal cancer Journal of Clinical Oncology, 2017, 35, 3562-3562.	1.6	1
156	Tumor-infiltrating lymphocytes (TILs) and expression of PD-L1 in melanoma brain metastases (BM) Journal of Clinical Oncology, 2014, 32, 9055-9055.	1.6	1
157	Improved Protoporphyrin IX-Guided Neurosurgical Tumor Detection with Frequency-Domain Fluorescence Lifetime Imaging. Applied Sciences (Switzerland), 2022, 12, 1002.	2.5	1
158	ACTR-32. 5-ALA FLUORESCENCE IS A POWERFUL MARKER FOR DETECTION OF UNEXPECTED GLIOBLASTOMA TISSUE DURING SURGERY OF RADIOLOGICALLY SUSPECTED LOW-GRADE GLIOMAS. Neuro-Oncology, 2018, 20, vi18-vi18.	1.2	0
159	CMET-26. PERIOPERATIVE IMAGING OF BRAIN METASTASES: A EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY (EANO) YOUNGSTERS SURVEY. Neuro-Oncology, 2018, 20, vi59-vi59.	1.2	0
160	SURG-13. EVALUATION OF 5-ALA FLUORESCENCE IN BRAIN METASTASES OF VARIOUS PRIMARY TUMORS: A MULTICENTER STUDY WITH EXPERIENCE IN 157 CASES. Neuro-Oncology Advances, 2019, 1, i33-i33.	0.7	0
161	TMIC-09. MULTIMODAL VISIBLE LIGHT OPTICAL COHERENCE MICROSCOPY AND FLUORESCENCE IMAGING OF GLIOBLASTOMA REGIONAL SAMPLES. Neuro-Oncology, 2019, 21, vi248-vi249.	1.2	0
162	BIMG-04. MAPPING HETEROGENEITY OF HIGH-GRADE GLIOMA METABOLISM USING HIGH RESOLUTION 7T MRSI. Neuro-Oncology Advances, 2021, 3, i1-i1.	0.7	0

#	Article	IF	CITATIONS
163	Correlation of large brain edema with favorable prognosis in patients with single brain metastases Journal of Clinical Oncology, 2012, 30, 2053-2053.	1.6	0
164	Health-related quality of life (HRQOL) in patients with glioblastoma (GBM) and their caregivers in the end-of-life phase: A retrospective study Journal of Clinical Oncology, 2012, 30, 2071-2071.	1.6	0
165	QOL and neurocognitive functions in patients with GBM Journal of Clinical Oncology, 2014, 32, 2062-2062.	1.6	0
166	Effect of laboratory parameters on prognostic value in patients with newly diagnosed brain metastases: Analysis of 1,207 cases Journal of Clinical Oncology, 2015, 33, e13034-e13034.	1.6	0
167	Combined visible light optical coherence microscopy and fluorescence imaging setup to investigate 5-aminolevulinic acid postive glioma samples. , 2019, , .		Ο
168	Radiation-induced changes in the inflammatory microenvironment composition of lung cancer brain metastases Journal of Clinical Oncology, 2020, 38, 2528-2528.	1.6	0
169	Reply to Stummer, W.; Thomas, C. Comment on "Hosmann et al. 5-ALA Fluorescence Is a Powerful Prognostic Marker during Surgery of Low-Grade Gliomas (WHO Grade II)—Experience at Two Specialized Centers. Cancers 2021, 13, 2540― Cancers, 2021, 13, 5705.	3.7	0
170	NIMG-13. RESPONSE ASSESSMENT IN GLIOBLASTOMA PATIENTS TREATED WITH DENDRITIC CELL-BASED IMMUNOTHERAPY: A COMPARATIVE ANALYSIS OF MACDONALD, RANO, MRANO, IRANO AND VOLUMETRIC MEASUREMENTS. Neuro-Oncology, 2021, 23, vi130-vi130.	1.2	0
171	Analysis of corticosteroid and antiepileptic drug treatment effects on heme biosynthesis mRNA expression in lower-grade gliomas: potential implications for 5-ALA metabolization. Photodiagnosis and Photodynamic Therapy, 2022, 38, 102755.	2.6	0